SCHEMBL5510043

SCHEMBL5510043

Cc1ccc2c(c1)C(=O)[N]C2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.52
MAOA P21397 1/20 0.52
ELANE P08246 1/20 0.50
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
ALKBH3 Q96Q83 2/20 0.41
USP8 P40818 1/20 0.41
USP7 Q93009 1/20 0.41
ADORA3 P0DMS8 1/20 0.39
METAP1 P53582 2/20 0.38
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
NQO1 P15559 2/20 0.38
POR P16435 2/20 0.38
LCK P06239 1/20 0.38
CHRM2 P08172 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17671420 0.77 MAOA (0.48) MAOBMAOAELANECA1CA2
SCHEMBL5158442 0.74 MAOA (0.45) MAOBMAOAELANECA1CA2
SCHEMBL31674914 0.72 ELANE (0.77) MAOBMAOAELANECA1CA2
SCHEMBL182959 0.72 ELANE (0.86) MAOBMAOAELANECA1CA2
SCHEMBL4402286 0.72 MAOA (0.73) MAOBMAOAELANECA1CA2
SCHEMBL12108763 0.72 MAOA (0.73) MAOBMAOAELANECA1CA2
SCHEMBL2610165 0.72 ELANE (0.77) MAOBMAOAELANECA1CA2
SCHEMBL4401141 0.72 ELANE (0.77) MAOBMAOAELANECA1CA2
SCHEMBL583153 0.72 ELANE (0.86) MAOBMAOAELANECA1CA2
SCHEMBL4141951 0.71 S100A4 (0.56) CA1CA2CA4CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11613618-B2 Porous body, and method for producing porous body EMAUS KYOTO, INC. (JP) 2023-03-28 US disclosed
US-20210214514-A1 POROUS BODY, AND METHOD FOR PRODUCING POROUS BODY EMAUS KYOTO, INC. (JP) 2021-07-15 US disclosed
EP-3789444-A1 POROUS BODY, AND METHOD FOR PRODUCING POROUS BODY Emaus Kyoto, Inc. (JP) 2021-03-10 EP disclosed
US-10858491-B2 Porous particle made of organic polymer, method for producing porous particle made of organic polymer, and block copolymer KYOTO UNIVERSITY (JP) 2020-12-08 US disclosed
EP-3327071-B1 POROUS PARTICLE MADE OF ORGANIC POLYMER, METHOD FOR PRODUCING POROUS PARTICLE MADE OF ORGANIC POLYMER UNIV KYOTO (JP) 2020-04-29 EP disclosed
US-20180223067-A1 POROUS PARTICLE, METHOD FOR PRODUCING POROUS PARTICLE, AND BLOCK COPOLYMER KYOTO UNIVERSITY (JP) 2018-08-09 US disclosed
EP-3327070-A1 POROUS PARTICLE, METHOD FOR PRODUCING POROUS PARTICLE, AND BLOCK COPOLYMER Kyoto University (JP) 2018-05-30 EP disclosed
EP-3327071-A1 POROUS PARTICLE MADE OF ORGANIC POLYMER, METHOD FOR PRODUCING POROUS PARTICLE MADE OF ORGANIC POLYMER, AND BLOCK COPOLYMER Kyoto University (JP) 2018-05-30 EP disclosed
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
EP-1146037-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS NIPPON SODA CO (JP) 2006-06-21 EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6410749-B1 REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND NIPPON SODA CO., LTD. (JP) 2002-06-25 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed
EP-1146037-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS NIPPON SODA CO., LTD. (JP) 2001-10-17 EP disclosed
EP-0686636-B1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA CO (JP) 2001-04-04 EP disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed
US-5840895-A INTERMEDIATES FOR ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1998-11-24 US disclosed
US-5686442-A ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1997-11-11 US disclosed
EP-0686636-A1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA KABUSHIKI KAISHA (JP) 1995-12-13 EP disclosed
US-4065471-A N-(4-Amino-2-butynyl)imides STERLING DRUG INC. (US) 1977-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 MAOB 58/4885MAOA 124/4885ELANE 2640/4885
US-10858491-B2 Porous particle made of organic polymer, method for producing porous particle made of organic polymer, and block copolymer SPOP, NUP205, ATP5PO MAOB 2327/4885MAOA 2484/4885ELANE 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.